These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8088260)

  • 41. A symposium: the cardiac arrhythmia suppression trial--does it alter our concepts of and approaches to ventricular arrhythmias? Woodland, Texas, August 9, 1989.
    Am J Cardiol; 1990 Jan; 65(4):1B-42B. PubMed ID: 2404393
    [No Abstract]   [Full Text] [Related]  

  • 42. Design and analysis of controlled clinical trials in rheumatic diseases.
    Williams HJ; Reading JC; Ward JR
    Clin Rheum Dis; 1983 Dec; 9(3):499-514. PubMed ID: 6606530
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Logarithmic transformations in ANOVA.
    Berry DA
    Biometrics; 1987 Jun; 43(2):439-56. PubMed ID: 3300800
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interim analyses and early termination of clinical trials.
    Choi SC
    J Biopharm Stat; 1997 Nov; 7(4):533-43. PubMed ID: 9358327
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Importance of pharmacokinetic studies in the clinical phase of experimentation with anti-arrhythmia agents].
    Jaillon P
    Arch Mal Coeur Vaiss; 1981 Dec; 74 Spec No():57-64. PubMed ID: 6803702
    [No Abstract]   [Full Text] [Related]  

  • 46. [Monitoring clinical studies. Development, measures and consequences].
    Pritsch M; Unnebrink K
    Med Klin (Munich); 2000 May; 95(1 Spec No):72-6. PubMed ID: 10851852
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical trials of arrhythmia management: methods or madness.
    Camm AJ
    Control Clin Trials; 1996 Jun; 17(3 Suppl):4S-16S. PubMed ID: 8877263
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.
    Stegert M; Kasenda B; von Elm E; You JJ; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Briel M;
    J Clin Epidemiol; 2016 Jan; 69():152-60. PubMed ID: 26361993
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Surrogate end points--somewhere between essential and not worth discussing].
    Glaeske G
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(3):161-7. PubMed ID: 22682411
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomizing responders. Cardiac Arrhythmia Suppression Trial (CAST) investigators.
    Hallstrom AP; Verter J; Friedman L
    Control Clin Trials; 1991 Aug; 12(4):486-503. PubMed ID: 1657526
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recommendations for myasthenia gravis clinical trials.
    Benatar M; Sanders DB; Burns TM; Cutter GR; Guptill JT; Baggi F; Kaminski HJ; Mantegazza R; Meriggioli MN; Quan J; Wolfe GI;
    Muscle Nerve; 2012 Jun; 45(6):909-17. PubMed ID: 22581550
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Cardiac arrhythmia in the active population (clinical guidelines for the practitioner) by the Working Group of the European Society of Cardiology].
    Rev Prat; 1981 Nov; 31(53):3891-2 passim. PubMed ID: 7313477
    [No Abstract]   [Full Text] [Related]  

  • 53. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact.
    Myerburg RJ; Mitrani R; Interian A; Castellanos A
    Circulation; 1998 Apr; 97(15):1514-21. PubMed ID: 9576433
    [No Abstract]   [Full Text] [Related]  

  • 54. Principles and problems of clinical trials: a European view.
    Tygstrup N
    Triangle; 1980; 19(3-4):93-6. PubMed ID: 7222225
    [No Abstract]   [Full Text] [Related]  

  • 55. The use of external monitoring committees in clinical trials of the National Institute of Allergy and Infectious Diseases.
    Ellenberg SS; Myers MW; Blackwelder WC; Hoth DF
    Stat Med; 1993 Mar; 12(5-6):461-7; discussion 469. PubMed ID: 8493424
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Multiplicity of inferences in clinical trials: adjustment methods, clinical interpretation issues].
    Jouan-Flahault C; Casset-Semanaz F; Minini P
    Med Sci (Paris); 2004 Feb; 20(2):231-5. PubMed ID: 14997445
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The training of statisticians for cooperative clinical trials: a working statistician's viewpoint.
    Gehan EA
    Biometrics; 1980 Dec; 36(4):699-706. PubMed ID: 7248438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment effects monitoring committees and early stopping in large clinical trials.
    Kiri A; Tonascia S; Meinert CL
    Clin Trials; 2004 Feb; 1(1):40-7. PubMed ID: 16281461
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monitoring of clinical trials: issues and recommendations.
    Fleming TR; DeMets DL
    Control Clin Trials; 1993 Jun; 14(3):183-97. PubMed ID: 8339549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials.
    Pocock SJ; Clayton TC; Stone GW
    J Am Coll Cardiol; 2015 Dec; 66(25):2886-2898. PubMed ID: 26718676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.